Low-birthweight children and those born small for their gestational age (SGA) are likely to be salt sensitive, according to study findings published online Aug. 11 in Hypertension.
Low-birthweight children and those born small for their gestational age (SGA) are likely to be salt sensitive, according to study findings published online Aug. 11 in Hypertension.
Giacomo D. Simonetti, MD, and colleagues from Bern University Hospital and University of Bern in Switzerland measured the glomerular filtration rate and salt sensitivity (a mean blood pressure increase of 3 mm Hg or more over 24 hours on a high-salt diet compared with a controlled-salt diet) in 50 white children (mean age 11.3 years). Of these, 35 were of low birthweight and 15 were of normal birthweight, and 25 were SGA and 25 were appropriate for gestational age.
The researchers found that the low-birthweight children had significantly higher baseline blood pressure, a significantly lower glomerular filtration rate, and significantly reduced kidney length and volume compared with children of normal birthweight. In addition, 37% of low-birthweight children and 47% of SGA children had salt sensitivity. There was a significant inverse correlation between salt sensitivity and kidney length but not glomerular filtration rate, the report indicates.
“We conclude that a reduced renal mass in growth-restricted children poses a risk for a lower renal function and for increased salt sensitivity,” Simonetti and colleagues write. “Whether the changes in renal growth are causative or are the consequence of the same abnormal ‘fetal programming’ awaits clarification.”
Simonetti GD, Raio L Surbek D, et al. Salt sensitivity of children with low birthweight.
Hypertension
. 2008;52:625-630
Mosie Baby Kit receives class 2 FDA clearance for intravaginal insemination
December 6th 2023Discover how Mosie Baby's at-home insemination kit, the first FDA-cleared of its kind, empowers individuals facing infertility challenges with an effective, easy-to-use solution for intravaginal insemination.
Read More
Daré Bioscience initiates phase 3 clinical trial for ovaprene contraceptive
December 5th 2023Daré Bioscience has commenced a pivotal phase 3 clinical trial for ovaprene, an intravaginal contraceptive that releases a locally acting agent to prevent sperm entry into the cervical canal, marking a significant step towards a non-hormonal contraceptive option for women.
Read More
Exploring menstrual health: Insights from the Avon longitudinal study
December 5th 2023Unveiling a comprehensive analysis of menstrual cycle characteristics in mothers and daughters, this article delves into the diverse features, potential risk factors, and the importance of understanding these nuances for effective menstrual health management.
Read More
How plasma biomarkers illuminate brain health in women with HIV
December 4th 2023Discoveries from a comprehensive study reveal specific plasma biomarkers that may serve as indicators of neurological well-being in individuals living with HIV, shedding light on potential links to Alzheimer's disease and emphasizing the importance of early detection for improved outcomes.
Read More